Developmental Pharmacology
description
Transcript of Developmental Pharmacology
![Page 1: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/1.jpg)
Developmental Developmental PharmacologyPharmacologyScaling adult doses to infants based on Scaling adult doses to infants based on body weight or surface area does not body weight or surface area does not account for developmental changes account for developmental changes
that affect drug disposition or that affect drug disposition or tissue/organ sensitivity.tissue/organ sensitivity.
Frank Balis, M.D.Frank Balis, M.D.February 22, 2007February 22, 2007
![Page 2: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/2.jpg)
ChloramphenicolChloramphenicol
• Natural product of Natural product of StreptomycesStreptomyces (1947) (1947)
• Inhibits protein synthesis (bacteriostatic)Inhibits protein synthesis (bacteriostatic)
• Eliminated by glucuronide conjugation (90%) Eliminated by glucuronide conjugation (90%) and renal excretion (<10%)and renal excretion (<10%)
• Nursery infections treated with high dosesNursery infections treated with high doses
O2N
NCl
Cl
O
OHH
HOH
![Page 3: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/3.jpg)
Chloramphenicol in InfantsChloramphenicol in Infants
• 3320 gm infant, 44 week gestation3320 gm infant, 44 week gestation
• Meconium stained, foul smelling, timing of ROM Meconium stained, foul smelling, timing of ROM unknownunknown
• Procaine penicillin (50,00 units) + chloramphenicol (250 Procaine penicillin (50,00 units) + chloramphenicol (250 mg) IM q8h - 230 mg/kg/day x 72 hrmg) IM q8h - 230 mg/kg/day x 72 hr
• Day 4, gray color & cold, moist skinDay 4, gray color & cold, moist skin
• Died at 106 hr, 8 hr after onset of vascular collapseDied at 106 hr, 8 hr after onset of vascular collapse
Sutherland, Am J Dis Child 97:761-7, 1959
![Page 4: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/4.jpg)
Chloramphenicol in Premature InfantsChloramphenicol in Premature Infants
All Infants 2001-2500 gmn Deaths n Deaths
No antibiotics 32 6 17 1Pen + strep 33 6 24 0
Chloramphenicol 30 19 16 8Pen + strep +
chloramphenicol 31 21 15 6
Burns et al., NEJM 261:1318-21, 1959Burns et al., NEJM 261:1318-21, 1959
Premature infants born ≥24 hrs after ROMPremature infants born ≥24 hrs after ROM
![Page 5: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/5.jpg)
Gray Baby SyndromeGray Baby Syndrome
0 10 20 30 40 50 60 70 80
No AntibioticsPen + StrepChloramphenicol
% of Infants% of Infants
JaundiceJaundice
VomitingVomiting
AnorexiaAnorexia
Resp. distressResp. distress
Abd. distentionAbd. distention
CyanosisCyanosis
Green stoolsGreen stools
LethargyLethargy
Ashen colorAshen color
DeathDeath
44
4.14.1
4.34.3
4.54.5
4.64.6
4.74.7
55
5.35.3
5.75.7
Burns et al., NEJM 261:1318-21, 1959Burns et al., NEJM 261:1318-21, 1959
![Page 6: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/6.jpg)
Chloramphenicol Blood LevelsChloramphenicol Blood Levels
0
50
100
150
200
0 1 2 3 4Day of LifeDay of Life
Total Nitro Total Nitro Compounds Compounds
[µg/ml][µg/ml]
Therapeutic rangeTherapeutic range
Chloramphenicol dosesChloramphenicol doses
Burns et al., NEJM 261:1318-21, 1959
![Page 7: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/7.jpg)
Chloramphenicol PharmacokineticsChloramphenicol Pharmacokinetics
Weiss et al., NEJM 262:787-94, 1960
4
68
10
30
50
0 12 24 36 48 60Time [hr]Time [hr]
Total Nitro Total Nitro Compounds Compounds
[µg/ml][µg/ml]
4-5 yrs. (n=3)4-5 yrs. (n=3)
1-2 days (n=5)1-2 days (n=5)
10-16 days (n=3)10-16 days (n=3) tt1/21/2 - 26 hrs - 26 hrs
tt1/21/2 - 4 hrs - 4 hrs
tt1/21/2 - 10 hrs - 10 hrs
![Page 8: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/8.jpg)
Repeated AdministrationRepeated Administration
0
5
10
15
20
25
30
0 5 10 15 20 25 30
Weiss et al., NEJM 262:787-94, 1960Day of LifeDay of Life
Total Nitro Total Nitro Compounds Compounds
[µg/ml][µg/ml]
![Page 9: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/9.jpg)
Drug Use in Infants and ChildrenDrug Use in Infants and Children
• Scaling adult doses based on body weight or surface Scaling adult doses based on body weight or surface area does not account for developmental changes that area does not account for developmental changes that affect drug disposition or tissue/organ sensitivity.affect drug disposition or tissue/organ sensitivity.
• Pharmacologic impact of developmental changes are Pharmacologic impact of developmental changes are often discovered when unexpected or severe toxicity in often discovered when unexpected or severe toxicity in infants and children leads to detailed pharmacologic infants and children leads to detailed pharmacologic studies.studies.
• Therapeutic tragedies could be avoided by performing Therapeutic tragedies could be avoided by performing pediatric pharmacologic studies during the drug pediatric pharmacologic studies during the drug development process (before wide-spread use of agents development process (before wide-spread use of agents in infants and children).in infants and children).
![Page 10: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/10.jpg)
ZidovudineZidovudine
• Synthetic nucleoside analogSynthetic nucleoside analog
• Inhibits HIV reverse transcriptaseInhibits HIV reverse transcriptase
• Eliminated by glucuronide conjugation (67%) and renal Eliminated by glucuronide conjugation (67%) and renal excretion (33%)excretion (33%)
• Perinatal therapy to prevent HIV transmissionPerinatal therapy to prevent HIV transmission
O
O
O
CH3HN
NHOCH2
N3
![Page 11: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/11.jpg)
Zidovudine in the NewbornZidovudine in the Newborn
0
1
2
3
4
5
6
7
0.1 1 10
Age [weeks]Age [weeks]
ZDV AUC ZDV AUC [µg•hr/ml][µg•hr/ml]
Boucher et al., J Pediatr 122:137-44, 1993Boucher et al., J Pediatr 122:137-44, 1993
![Page 12: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/12.jpg)
Zidovudine in NewbornsZidovudine in Newborns
Boucher et al., J Pediatr 125:642-9, 1994Boucher et al., J Pediatr 125:642-9, 1994Mirochnick et al., Antimicrob Agents Chemother 42:808-12, 1998Mirochnick et al., Antimicrob Agents Chemother 42:808-12, 1998
Balis et al., J Pediatr 114:880-4, 1989Balis et al., J Pediatr 114:880-4, 1989Klecker et al., Clin Pharmacol Ther 41: 407-12, 1987Klecker et al., Clin Pharmacol Ther 41: 407-12, 1987
![Page 13: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/13.jpg)
Prevention of HIV TransmissionPrevention of HIV Transmission
0 3 6 9 12 15 18
0
1
2
3
6
12
Hemoglobin [g/dl]Hemoglobin [g/dl]
Age Age [weeks][weeks]
ZidovudineZidovudinePlaceboPlacebo
Connor et al., NEJM 331:1173-80, 1994Connor et al., NEJM 331:1173-80, 1994
![Page 14: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/14.jpg)
Ontogeny and PharmacologyOntogeny and Pharmacology
• Excretory organ (liver and kidneys) Excretory organ (liver and kidneys) development has the greatest impact on drug development has the greatest impact on drug disposition (pharmacokinetics)disposition (pharmacokinetics)
• The most dramatic changes occur during the The most dramatic changes occur during the first days to months of lifefirst days to months of life
• Anticipate age-related differences in drug Anticipate age-related differences in drug disposition based on knowledge of ontogenydisposition based on knowledge of ontogeny
• Effect of ontogeny on tissue/organ sensitivity to Effect of ontogeny on tissue/organ sensitivity to drugs (pharmacodynamics) is poorly studieddrugs (pharmacodynamics) is poorly studied
• Disease states may alter a drug’s PK/PDDisease states may alter a drug’s PK/PD
![Page 15: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/15.jpg)
• Glomerular filtration rateGlomerular filtration rate– Low at birthLow at birth
• Full term newborn - 10-15 ml/min/mFull term newborn - 10-15 ml/min/m22
• Premature - 5-10 ml/min/mPremature - 5-10 ml/min/m22
– GFR doubles by 1 week of ageGFR doubles by 1 week of age– Adult values by 6-12 months of ageAdult values by 6-12 months of age
• Tubular functionTubular function– Secretory function impaired at birthSecretory function impaired at birth– Glomerulotubular imbalanceGlomerulotubular imbalance– Adult values by 1 year of ageAdult values by 1 year of age
Renal OntogenyRenal Ontogeny
![Page 16: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/16.jpg)
Glomerular Filtration RateGlomerular Filtration Rate
0
20
40
60
80
100
120
140
160
0 2 4 6 8 10 12 14
GFR GFR [ml/min/1.73 m[ml/min/1.73 m22]]
Age [months]Age [months]Aperia, Acta Pædiatr Scand 64:393-8, 1975
![Page 17: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/17.jpg)
0
10
20
30
40
50
60
0 5 10 15 20 25
GFR in InfantsGFR in Infants
GFR GFR [ml/min/1.73 m[ml/min/1.73 m22]]
Age [days]Age [days]Guignard, J Pediatr 87:268-72, 1975Guignard, J Pediatr 87:268-72, 1975
![Page 18: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/18.jpg)
Gentamicin in the NewbornGentamicin in the Newborn
0
20
40
60
80
100
120
0 20 40 60 80 100 120
Gentamicin Gentamicin Clearance Clearance [ml/kg•hr][ml/kg•hr]
Creatinine Clearance [ml/kg•hr]Creatinine Clearance [ml/kg•hr]
15 full term15 full term23 premature23 premature
Koren et al., Clin Pharmacol Ther 38:680-5, 1985
![Page 19: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/19.jpg)
0.04 0.06 0.08 0.1 0.12
0-2 days
3-7 days
8 days
Gentamicin ClearanceGentamicin Clearance
Postnatal Postnatal AgeAge
Gentamicin Clearance [L/kg•hr]Gentamicin Clearance [L/kg•hr]
Premature (<37 weeks)Premature (<37 weeks)
Full termFull term
Pons, Ther Drug Monit 10:421-7, 1988
![Page 20: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/20.jpg)
• Phase 1 Phase 1 (oxidation, hydrolysis, reduction, demethylation)(oxidation, hydrolysis, reduction, demethylation)– Activity low at birthActivity low at birth– Mature at variable ratesMature at variable rates
• Oxidative metabolism increases rapidly after birthOxidative metabolism increases rapidly after birth• Alcohol dehydrogenase reaches adult levels at 5 yrsAlcohol dehydrogenase reaches adult levels at 5 yrs
– Activity in young children exceeds adult levelsActivity in young children exceeds adult levels• Phase 2Phase 2 (conjugation, acetylation, methylation)(conjugation, acetylation, methylation)
– Conjugation:Conjugation:• Glucuronidation Glucuronidation at birthat birth• Sulfatation Sulfatation at birth at birth
– Acetylation Acetylation at birth, “fast” or “slow” at birth, “fast” or “slow” phenotype by 12-15 mo.phenotype by 12-15 mo.
Hepatic OntogenyHepatic Ontogeny
![Page 21: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/21.jpg)
Cytochrome P450 (CYP) EnzymesCytochrome P450 (CYP) Enzymes
• Superfamily of Phase 1 enzymes (oxidation, demethylation)Superfamily of Phase 1 enzymes (oxidation, demethylation)
• Nomenclature:Nomenclature:
• 17 Families and 39 subfamilies in humans17 Families and 39 subfamilies in humans
• CYP1, CYP2, CYP3 are primary drug metabolizing enzymesCYP1, CYP2, CYP3 are primary drug metabolizing enzymes
• Half of all drugs metabolized by CYP3A subfamilyHalf of all drugs metabolized by CYP3A subfamily
• CYP3A4 is most abundant hepatic P450 enzyme and CYP3A4 is most abundant hepatic P450 enzyme and metabolizes at least 50 drugsmetabolizes at least 50 drugs
CYP3A4CYP3A4Family (>40%)Family (>40%) Subfamily (>55%)Subfamily (>55%)
IsoformIsoform
![Page 22: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/22.jpg)
CYP OntogenyCYP Ontogeny
0
30
60
90
120
150
180
<24
hr
1-7
days
8-28
day
s
1-3
mo
3-12
mo
1-10
yr
Ontogeny of CYP Enzymes
CYP3A4CYP1A2CYP2D6UGT2B7
Perc
ent A
dult
Act
ivity
Kearns GL et al. NEJM 349: 1157, 2003Kearns GL et al. NEJM 349: 1157, 2003
![Page 23: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/23.jpg)
CYP2E1 Ontogeny
0
20
40
60
80
100
3rd
trim
este
r
0-30
day
s
31-9
0 da
ys
91 d
-18
yr
CYP2E1 Ontogeny
CY
P2E
1 [%
Adu
lt L
evel
]
![Page 24: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/24.jpg)
CYP3A OntogenyCYP3A Ontogeny
0
0.5
1
1.5
0
0.05
0.1
0.15
<30w<30w>30w>30w<24h<24h1-7d1-7d8-28d8-28d1-3m
o1-3m
o3-12m
o3-12m
o>1yr>1yrAdultAdult
FetusFetusPostnatal AgePostnatal Age
CYP3A7 CYP3A7 ActivityActivity
CYP3A4 CYP3A4 ActivityActivity
LaCroix D et al. Eur J Biochem 247:625, 1997LaCroix D et al. Eur J Biochem 247:625, 1997
![Page 25: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/25.jpg)
0.30.3
0.750.75
1.61.6
1.81.8
G:SG:S
Acetaminophen MetabolismAcetaminophen Metabolism
0 20 40 60 80 100
Newborn
3-9 years
12 years
Adults
AcetaminophenGlucuronideSulfate
Miller et al., Clin Pharmacol Ther 19:284-94, 1976
0.150.15
0.170.17
0.190.19
0.180.18
kkelel
% of Dose% of Dose
![Page 26: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/26.jpg)
Theophylline Urinary MetabolitesTheophylline Urinary Metabolites
0 20 40 60 80 100
28-32 weeks
40-50 weeks
2-3 years
4-9 years
10-16 years
TheophyllineCaffiene3-MeX1-MeUA1,3-diMeUA
% Recovered in Urine% Recovered in Urine
Post-Post-conception conception
AgeAge
Age Age RangeRange
Clearance Clearance [ml/min/kg][ml/min/kg]
2020
7070
100100
![Page 27: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/27.jpg)
Factors Affecting Drug DistributionFactors Affecting Drug Distribution
• Physicochemical properties of the drugPhysicochemical properties of the drug
• Cardiac output/Regional blood flowCardiac output/Regional blood flow
• Degree of protein/tissue bindingDegree of protein/tissue binding
• Body compositionBody composition– Extracellular waterExtracellular water
– Adipose tissueAdipose tissue
![Page 28: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/28.jpg)
Ontogeny of Body CompositionOntogeny of Body Composition
% of Total Body Weight% of Total Body Weight
EC HEC H22OO IC HIC H22OOProteinProtein OtherOther
FatFat
0 20 40 60 80 100
Premature
Newborn
4 mo
12 mo
24 mo
36 mo
Adult
Kaufman, Pediatric Pharmacology (Yaffe & Aranda, eds) pp. 212-9, 1992Kaufman, Pediatric Pharmacology (Yaffe & Aranda, eds) pp. 212-9, 1992
![Page 29: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/29.jpg)
Volume of Distribution of SulfaVolume of Distribution of Sulfa
0 0.1 0.2 0.3 0.4 0.5
Newborn
Infant
Children
Adults
Elderly
Volume of Distribution [L/kg]Volume of Distribution [L/kg]Routledge, J Antimicrob Chemother 34 Suppl A:19-24, 1994
![Page 30: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/30.jpg)
Tissue and Organ WeightTissue and Organ Weight
% of Total Body WeightFetus Newborn Adult
Skeletal muscle 25 25 40Skin 13 4 6
Skeleton 22 18 14Heart 0.6 0.5 0.4Liver 4 5 2
Kidneys 0.7 1 0.5Brain 13 12 2
% of Total Body WeightFetus Newborn Adult
Skeletal muscle 25 25 40Skin 13 4 6
Skeleton 22 18 14Heart 0.6 0.5 0.4Liver 4 5 2
Kidneys 0.7 1 0.5Brain 13 12 2
![Page 31: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/31.jpg)
Plasma ProteinsPlasma Proteins
Change from Adult ValuesNewborn Infant Child
Total protein
Albumin
1-Acid glycoprotein
Fetal albumin Present Absent AbsentGlobulin
![Page 32: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/32.jpg)
Protein Binding in Cord and Adult PlasmaProtein Binding in Cord and Adult Plasma
Kurz et al., Europ J Clin Pharmacol II:463-7, 1977
30.230.2 17.317.3
![Page 33: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/33.jpg)
CSF MTX and AgeCSF MTX and Age
0.001
0.01
0.1
1
10
1 2 3 4 5 6 7 8 9
AdultsAdolescentsChildren
Time [days]
CSF Methotrexate
[µM]
Bleyer, Cancer Treat Rep 61:1419-25, 1977
![Page 34: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/34.jpg)
CNS Growth and DevelopmentCNS Growth and Development
Birth 4 8 12 16 20 24
20
40
60
80
100
Age [yrs]
Adult Value
[%]
CNS Volume
Body Surface Area
Bleyer, Cancer Treat Rep 61:1419-25, 1977
![Page 35: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/35.jpg)
Adaptive IT MTX Dosing RegimenAdaptive IT MTX Dosing Regimen
Bleyer, Cancer Treat Rep 61:1419-25, 1977
![Page 36: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/36.jpg)
Dose Change with Adaptive RegimenDose Change with Adaptive Regimen
0
-25
+25
+50
+75
1.5 4 7 10 13Age [yrs]
% Change in Dose
Adaptive dose12 mg/m2 dose X 100
Bleyer, J Clin Oncol 1:317-25, 1983
![Page 37: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/37.jpg)
Effect of Adaptive IT Dosing on OutcomeEffect of Adaptive IT Dosing on Outcome
Incidence ofCNS Relapse
[%]
MTX Dose Based on BSA
MTX Dose Based on Age
Age [months]
Concurrent
Isolated
0
10
0
10
20
<18 18-35
36-83
84-119
≥12
Bleyer, J Clin Oncol 1:317-25, 1983
![Page 38: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/38.jpg)
Dosing Based on Body Surface AreaDosing Based on Body Surface Area• BSA = 2-dimensional surface area of the skinBSA = 2-dimensional surface area of the skin
• Estimated from formulas using weight & heightEstimated from formulas using weight & height
• Correlation between BSA and kidney/liver Correlation between BSA and kidney/liver function is weakfunction is weak
• BSA dosing evolved from scaling doses from BSA dosing evolved from scaling doses from animals to humans (toxicology)animals to humans (toxicology)
SpeciesSpecies Wt [kg]Wt [kg] BSA [mBSA [m22]] Dose [mg]Dose [mg] Dose [mg/kg]Dose [mg/kg] Dose [mg/mDose [mg/m22]]MouseMouse 0.0180.018 0.00750.0075 0.0270.027 1.51.5 3.63.6
RatRat 0.250.25 0.0450.045 0.1250.125 0.50.5 2.82.8
InfantInfant 88 0.40.4 1.251.25 0.150.15 3.13.1
ChildChild 2020 0.80.8 2.52.5 0.120.12 3.13.1
AdultAdult 7070 1.851.85 5.05.0 0.070.07 2.72.7
Pinkel, Cancer Res 18:853, 1958Pinkel, Cancer Res 18:853, 1958
![Page 39: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/39.jpg)
Liver Function (Children)Liver Function (Children)
Murry et al. Drug Metab Disp 23:1110, 1995Murry et al. Drug Metab Disp 23:1110, 1995
400
600
800
1000
1200
1400
1600
1800
0.5 1 1.5 2
BSA [mBSA [m22]]
Liver Vol Liver Vol [ml][ml]
rr22=0.75=0.750
10
20
30
40
50
0.5 1 1.5 2
AP CL AP CL [ml/min][ml/min]
rr22=0.04=0.04
![Page 40: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/40.jpg)
Excretory Organ GrowthExcretory Organ Growth
Age [yr]Age [yr]
Liver Liver [g][g]
Kidney Kidney [g/m[g/m22]]
Kidney Kidney [g/kg][g/kg]
Kidney Kidney [g][g]
Liver Liver [g/m[g/m22]]
Liver Liver [g/kg][g/kg]
0
500
1000
1500
0
50
100
150
200
250
300
0 3 6 9 12 15 18400
500
600
700
800
900
115
120
125
130
135
140
145
150
155
0 3 6 9 12 15 1820
25
30
35
3
4
5
6
7
0 3 6 9 12 15 18
![Page 41: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/41.jpg)
Body Weight :Surface AreaBody Weight :Surface Area
0
5
10
15
20
25
30
35
40
0 5 10 15 20 25Age [yrs]Age [yrs]
WeightWeightBSABSA
AdultAdult1 mg/kg = 40 mg/m1 mg/kg = 40 mg/m22
Dose = 70 mgDose = 70 mg
1 y.o.1 y.o.1 mg/kg = 10 mg1 mg/kg = 10 mg
40 mg/m40 mg/m22 = 18 mg = 18 mg
![Page 42: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/42.jpg)
Anticancer Drug ClearanceAnticancer Drug Clearance
McLeod et al., Br J Cancer 66 (Suppl. 18):S23-S29, 1992McLeod et al., Br J Cancer 66 (Suppl. 18):S23-S29, 1992
DRUGROUTE OF
ELIMINATIONCLINFANTS VSCLCHILDREN DOSING
Methotrexate R (15%) No adjustmentsMercaptopurine M ND No adjustments
Vincristine M (/m2) <1 yo, dose/kgVM26/VP16 M ND (/m2) No adjustments (/m2)
Doxorubicin B, M (/m2) <2 yo, dose/kg or Źdose/m2
Cytarabine M ND No adjustment
![Page 43: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/43.jpg)
Vincristine ClearanceVincristine Clearance
0 100 200 300 400 500
Infants
Children
Adolescents
0 5 10 15 20 25
Infants
Children
Adolescents
Vincristine Clearance Vincristine Clearance [ml/min/[ml/min/mm22]]
Vincristine Clearance Vincristine Clearance [ml/min/[ml/min/kgkg]]
Crom et al., J Pediatr 125:642-9, 1994Crom et al., J Pediatr 125:642-9, 1994
![Page 44: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/44.jpg)
Etoposide ClearanceEtoposide Clearance
0
5
10
15
20
25
30
p = 0.5
<1 yr(n=5)
>1 yr(n=25)
<1 yr(n=5)
>1 yr(n=25)
p = 0.004
0
1.2
0.8
0.4
EtoposideEtoposideClearanceClearance
[ml/min/[ml/min/mm22]]
EtoposideEtoposideClearanceClearance[ml/min/[ml/min/kgkg]]
![Page 45: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/45.jpg)
Doxorubicin ClearanceDoxorubicin Clearance
10
20
30
40
50
60
70
80
90
<2 yr(n=8)
>2 yr(n=52)
p = 0.39
0
500
1000
1500
2000
2500
<2 yr(n=8)
>2 yr(n=52)
p = 0.015
DoxorubicinDoxorubicinClearanceClearance
[ml/min/[ml/min/mm22]]
DoxorubicinDoxorubicinClearanceClearance[ml/min/[ml/min/kgkg]]
![Page 46: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/46.jpg)
Oral Busulfan (16-30 mg/kg)Oral Busulfan (16-30 mg/kg)
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
EngraftmentEngraftment
Graft rejectionGraft rejection
Age [yrs]Age [yrs]
Busulfan CBusulfan Cssss [ng/ml][ng/ml]
Slattery et al., Bone Marrow Transplant 16:31, 1995Bone Marrow Transplant 16:31, 1995
![Page 47: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/47.jpg)
Drug Clearance in Cystic FibrosisDrug Clearance in Cystic Fibrosis
0 20 40 60 80 100 120 140
Gentamycin
Ticarcillin
Ceftazidime
Cloxacillin (NR)
Theophylline
Furosemide (NR)
Ibuprofen
Clearance [ml/min•m2]
Renal
Hepatic
Rey, Clin Pharmacokinet 35:313-29, 1998
Cystic FibrosisControls
![Page 48: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/48.jpg)
RetinoidsRetinoids
≤≤12 Yr.12 Yr. >12 Yr>12 Yr AdultAdultATRAATRA
MTDMTD 60 mg/m60 mg/m22/d/d 90 mg/m90 mg/m22/d/d 150 mg/m150 mg/m22/d/d
DLTDLT Pseudotumor Pseudotumor cerebricerebri
HA and PCHA and PC DermatologicDermatologic
9-cis-RA9-cis-RAMTDMTD 35 mg/m35 mg/m22/d/d 85 mg/m85 mg/m22/d/d 140 mg/m140 mg/m22/d/d
DLTDLT Pseudotumor Pseudotumor cerebricerebri
HA and PCHA and PC HA, HA, diarrhea, diarrhea,
dermatologicdermatologic
![Page 49: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/49.jpg)
ConclusionsConclusions
• Infants (esp. newborns) may have reduced Infants (esp. newborns) may have reduced capacity to eliminate drugscapacity to eliminate drugs
• Anticipate the effects of ontogeny on drug Anticipate the effects of ontogeny on drug disposition based on route of eliminationdisposition based on route of elimination
• More systematic pharmacokinetic studies of More systematic pharmacokinetic studies of drugs in infants are neededdrugs in infants are needed
• Tissue sensitivity to the toxic effects of drugs Tissue sensitivity to the toxic effects of drugs may be age-dependentmay be age-dependent
![Page 50: Developmental Pharmacology](https://reader035.fdocuments.us/reader035/viewer/2022081503/56816837550346895dddfb08/html5/thumbnails/50.jpg)